Alivus Life Sciences Ltd

- There is an ongoing internal discussion and process related to promoter holding dilution to comply with SEBI regulations, requiring promoter holding to reduce to 75%. This implies potential stake sale or equity dilution. - Glenmark Pharma is approaching some investors for stake sale, and management has participated in these discussions. - No explicit mention of new debt fundraising. - Capex guidance for FY24 is INR 150-200 crores, to be funded internally as the company remains net debt-free with strong cash balances. - Free cash flow generation is strong, and the company plans to continue distributing free cash mostly through dividends. - Management aims to be measured and cautious in capital allocation and fundraising, with plans to grow the CDMO business and overall capacity cautiously.

- Dahej capacity was brought online in Q4 and has already reached 80% utilization; additional capacity expansions will continue to avoid disadvantaging the business. - Backward integration project is partially commissioned; full capacity expected this year, with a commercial project starting Q2 expected to improve gross margin by 5%-7% on a ~INR100 crore product. - Solapur capex to commence construction this financial year, planned in phases; capacity is multipurpose for both CDMO and generics. - FY’24 capex guidance is INR150-200 crores, continuing calibrated investment approach. - Industry capex buildup continues but is calibrated; Glenmark's multipurpose and fungible capacities reduce the need for large investments. - Working capital days peaked at 178 in Q3 and expected to reduce slightly to around 160-170 days going forward. - Free cash flow generation will support continued dividend payouts alongside capex requirements.

- The company expects revenue growth of around 12% to 15% for FY24, maintaining conservative guidance despite strong Q4 performance. - Growth is largely volume-driven, with new products and capacity expansions contributing significantly. - The Dahej facility capacity brought online in Q4 has reached 80% utilization, signaling a strong growth lever going forward. - The external business, especially regulated markets, showed growth normalization in second half and strong demand in Q4. - The CDMO segment aims to double its revenue contribution from approx. INR150-170 crores (7-8%) to around 15% over 4-5 years, implying potential revenue of INR600 crores. - Introduction of new complex molecules, oncology compounds, and geographic expansion expected to drive future growth. - The product basket expanded to 139 molecules with 700 customers globally, supporting diversified growth. - Despite pricing pressures, especially in the US market, margins are expected to remain sustainable due to product diversity and new product introductions.

- Glenmark Life Sciences expects revenue growth of 12-15% for FY24, maintaining a stable outlook despite Q4’s strong performance which was slightly above guidance. - EBITDA margin guidance is around 30-31%, with a possibility of reaching ~33% if all growth levers fire positively, but the company remains cautious due to market volatility. - The company aims to nearly double certain segments (e.g., from INR150 crores to INR600 crores in ~4-5 years), indicating robust medium-term growth ambitions, especially in complex APIs, iron compounds, and oncology. - PAT saw a 39% sequential growth in Q4 and 48% YoY, reflecting improved profitability driven by better gross margins and lower costs, with continued margin sustainability expected. - The business pipeline includes 139 molecules and 20 complex molecules in the R&D pipeline, supporting sustainable long-term growth. - Free cash flow generation of INR200-300 crores annually supports dividends and reinvestment.

- The transcript does not explicitly mention current or expected orderbook or pending orders in quantified terms. - However, the management indicates strong demand recovery and capacity utilization: - Dahej capacity brought online in Q4 already at 80% utilization, indicating robust order inflow. - Good visibility on business with numerous new molecules and customers contributing to a pipeline of around 140 molecules. - Increasing momentum in China de-risking leading to new customer filings and diversified supply chains. - Growth levers include high-complexity APIs, iron compounds, and oncology compounds. - CDMO projects have picked up due to additional customer indications and inventory rationalizations. - Overall, management expresses optimism about demand and intends to stick to their growth guidance with no specific order backlog numbers disclosed.